Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)

NCT00125034 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm Metastasis
Colorectal Cancer

Interventions

BIOLOGICAL: Cetuximab
DRUG: Oxaliplatin

Sponsor

Merck KGaA, Darmstadt, Germany